Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Junia V. Melo et al.|Blood|2013Cited by 705
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2014Cited by 198
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human TrialConstantine S. Tam, Andrew W. Roberts, Andrew Grigg et al.|Blood|2015Cited by 111
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Michael Osborn et al.|Blood|2014Cited by 102
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsTimothy P. Hughes, David M. Ross, Ilaria S. Pagani et al.|Leukemia|2018Cited by 78